RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 68 filers reported holding RUBIUS THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $184,000 | -49.2% | 425,497 | 0.0% | 0.00% | -100.0% |
Q2 2022 | $362,000 | -85.4% | 425,497 | -5.8% | 0.00% | -80.0% |
Q1 2022 | $2,487,000 | +2140.5% | 451,505 | +3765.3% | 0.01% | +400.0% |
Q4 2019 | $111,000 | -96.1% | 11,681 | -92.7% | 0.00% | -92.9% |
Q1 2019 | $2,878,000 | – | 159,046 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 2,618,351 | $41,187,000 | 42.64% |
Flagship Pioneering Inc. | 38,296,526 | $602,404,000 | 26.08% |
HARBOURVEST PARTNERS LLC | 1,973,756 | $31,048,000 | 5.81% |
Artal Group S.A. | 2,833,791 | $44,576,000 | 1.80% |
EcoR1 Capital, LLC | 463,152 | $7,285,000 | 0.74% |
Cormorant Asset Management, LP | 600,000 | $9,438,000 | 0.54% |
Nikko Asset Management Americas, Inc. | 1,254,158 | $19,728,000 | 0.39% |
Leap Investments LP | 14,100 | $222,000 | 0.30% |
ARK Investment Management | 698,402 | $10,986,000 | 0.28% |
Baillie Gifford | 4,234,682 | $66,612,000 | 0.07% |